TY - JOUR
T1 - Nonchromosomal birth defects and risk of childhood acute leukemia
T2 - An assessment in 15 000 leukemia cases and 46 000 controls from the Childhood Cancer and Leukemia International Consortium
AU - Lupo, Philip J.
AU - Chambers, Tiffany M.
AU - Mueller, Beth A.
AU - Clavel, Jacqueline
AU - Dockerty, John D.
AU - Doody, David R.
AU - Erdmann, Friederike
AU - Ezzat, Sameera
AU - Filippini, Tommaso
AU - Hansen, Johnni
AU - Heck, Julia E.
AU - Infante-Rivard, Claire
AU - Kang, Alice Y.
AU - Magnani, Corrado
AU - Malagoli, Carlotta
AU - Metayer, Catherine
AU - Bailey, Helen D.
AU - Mora, Ana M.
AU - Ntzani, Evangelia
AU - Petridou, Eleni Th
AU - Pombo-de-Oliveira, Maria S.
AU - Rashed, Wafaa M.
AU - Roman, Eve
AU - Schüz, Joachim
AU - Wesseling, Catharina
AU - Spector, Logan G.
AU - Scheurer, Michael E.
N1 - Funding Information:
: The AUS‐ALL consortium conducted the AUS‐ALL study and the Telethon Kids Institute (formerly Telethon Institute for Child Health Research; TICHR), University of Western Australia, was the coordinating center. Bruce Armstrong (Sydney School of Public Health), Elizabeth Milne (TICHR), Frank van Bockxmeer (Royal Perth Hospital), Michelle Haber (Children's Cancer Institute Australia), Rodney Scott (University of Newcastle), John Attia (University of Newcastle), Murray Norris (Children's Cancer Institute Australia), Carol Bower (TICHR), Nicholas de Klerk (TICHR), Lin Fritschi (WA Institute for Medical Research, WAIMR), Ursula Kees (TICHR), Margaret Miller (Edith Cowan University), Judith Thompson (WA Cancer Registry) were the research investigators, and H4elen Bailey (TICHR) was the project coordinator. The clinical investigators were: Frank Alvaro (John Hunter Hospital, Newcastle); Catherine Cole (Princess Margaret Hospital for Children, Perth); Luciano Dalla Pozza (Children's Hospital at Westmead, Sydney); John Daubenton (Royal Hobart Hospital, Hobart); Peter Downie (Monash Medical Centre, Melbourne); Liane Lockwood (Royal Children's Hospital, Brisbane); Maria Kirby (Women's and Children's Hospital, Adelaide); Glenn Marshall (Sydney Children's Hospital, Sydney); Elizabeth Smibert (Royal Children's Hospital, Melbourne); Ram Suppiah (previously Mater Children's Hospital, Brisbane). AUS‐ALL was funded by the National Health and Medical Research Council of Australia Grant Number 254539. : Research reported in this publication was supported by the U.S. Department of Defense under award numbers CA190214 and W81XW‐H2‐0‐10567 (PJ Lupo), the National Institutes of Health under award numbers R01CA249867, R03CA272955, R01CA284531 (PJ Lupo), and the Cancer Prevention and Research Institute of Texas under award numbers RP210064 and RP160771 (ME Scheurer). : The CCLS thanks the families for their participation and the clinical investigators at the following collaborating hospitals for help in recruiting patients: University of California Davis Medical Center (Dr. J. Ducore), University of California San Francisco (Drs. M. Loh and K. Matthay), Children's Hospital of Central California (Dr. V. Crouse), Lucile Packard Children's Hospital (Dr. G. Dahl), Children's Hospital Oakland (Dr. J. Feusner), Kaiser Permanente Roseville (former Sacramento; Drs. K. Jolly and V. Kiley), Kaiser Permanente Santa Clara (Drs. C. Russo, A. Wong, and D. Taggart), Kaiser Permanente San Francisco (Dr. K. Leung), and Kaiser Permanente Oakland (Drs. D. Kronish and S. Month). Finally, the CCLS thanks the entire study staff and former University of California, Berkeley Survey Research Center for their effort and dedication. This work was supported by the National Institute for Environmental Health Sciences (NIEHS) grants R01ES009137, P42ES004705, R24ES028524, and P01ES018172, the United States Environmental Protection Agency grant RD83451101, and with the additional support from the Children with Cancer UK (CWCUK). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funding sponsors. Research reported in this publication was supported by the National Institutes of Health under award number R01CA266253 (LG Spector). : The authors wish to acknowledge the contribution of the network (narechem.gr) of pediatric hematologists‐oncologists, radiologists, immunologists, and pediatricians who made this study possible; the field coordinator Evanthia Bouka, MPH and the statisticians Nick Dessypris, MSc, PhD and George Markozannes MSc, PhD Continuous clinical support by Margarita Baka, MD (Department of Pediatric Hematology‐Oncology, “P&A Kyriakou” Children's Hospital, Athens), Maria Moschovi, MD, Sophia Polychronopoulou, MD (Departments of Pediatric Hematology‐Oncology, “A. Sophia” Children's Hospital, Athens); Emmanuel Hatzipantelis MD, PhD (Pediatric Hematology Oncology Unit, second Pediatric Department of Aristotle University, AHEPA General Hospital, Thessaloniki); Maria Kourti, MD (Pediatric Oncology Department, Hippokration Hospital, Thessaloniki); Eftychia Stiakaki, MD (Department of Pediatric Hematology‐Oncology, University Hospital of Heraklion, Heraklion); Maria Karalexi and Ioannis Matsoukis, MD (Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, 11 527 Athens) should be also acknowledged. The Study has been supported in part since 1996 by the Hellenic Society for Social Pediatrics and Health Promotion. AUS‐ALL Baylor College of Medicine California Childhood Leukemia Study Children's Cancer Group: NARECHEM‐ST
Publisher Copyright:
© 2023 UICC.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Although recent studies have demonstrated associations between nonchromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer and Leukemia International Consortium, we evaluated associations between nonchromosomal birth defects and childhood leukemia. Pooling consortium data from 18 questionnaire-based and three registry-based case-control studies across 13 countries, we used multivariable logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between a spectrum of birth defects and leukemia. Our analyses included acute lymphoblastic leukemia (ALL, n = 13 115) and acute myeloid leukemia (AML, n = 2120) cases, along with 46 172 controls. We used the false discovery rate to account for multiple comparisons. In the questionnaire-based studies, the prevalence of birth defects was 5% among cases vs 4% in controls, whereas, in the registry-based studies, the prevalence was 11% among cases vs 7% in controls. In pooled adjusted analyses, there were several notable associations, including (1) digestive system defects and ALL (OR = 2.70, 95% CI: 1.46-4.98); (2) congenital anomalies of the heart and circulatory system and AML (OR = 2.86, 95% CI: 1.81-4.52) and (3) nervous system defects and AML (OR = 4.23, 95% CI: 1.50-11.89). Effect sizes were generally larger in registry-based studies. Overall, our results could point to novel genetic and environmental factors associated with birth defects that could also increase leukemia susceptibility. Additionally, differences between questionnaire- and registry-based studies point to the importance of complementary sources of birth defect phenotype data when exploring these associations.
AB - Although recent studies have demonstrated associations between nonchromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer and Leukemia International Consortium, we evaluated associations between nonchromosomal birth defects and childhood leukemia. Pooling consortium data from 18 questionnaire-based and three registry-based case-control studies across 13 countries, we used multivariable logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between a spectrum of birth defects and leukemia. Our analyses included acute lymphoblastic leukemia (ALL, n = 13 115) and acute myeloid leukemia (AML, n = 2120) cases, along with 46 172 controls. We used the false discovery rate to account for multiple comparisons. In the questionnaire-based studies, the prevalence of birth defects was 5% among cases vs 4% in controls, whereas, in the registry-based studies, the prevalence was 11% among cases vs 7% in controls. In pooled adjusted analyses, there were several notable associations, including (1) digestive system defects and ALL (OR = 2.70, 95% CI: 1.46-4.98); (2) congenital anomalies of the heart and circulatory system and AML (OR = 2.86, 95% CI: 1.81-4.52) and (3) nervous system defects and AML (OR = 4.23, 95% CI: 1.50-11.89). Effect sizes were generally larger in registry-based studies. Overall, our results could point to novel genetic and environmental factors associated with birth defects that could also increase leukemia susceptibility. Additionally, differences between questionnaire- and registry-based studies point to the importance of complementary sources of birth defect phenotype data when exploring these associations.
KW - acute lymphoblastic leukemia
KW - acute myeloid leukemia
KW - birth defects
KW - childhood leukemia
KW - epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85170522256&partnerID=8YFLogxK
U2 - 10.1002/ijc.34720
DO - 10.1002/ijc.34720
M3 - Article
C2 - 37694915
AN - SCOPUS:85170522256
SN - 0020-7136
VL - 154
SP - 434
EP - 447
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 3
ER -